Simbarashe Zvada - Concepedia

Author

Simbarashe Zvada

University of Cape Town

Also Known As

S Zvada, S. P. Zvada, Simbarashe P. Zvada, Simbarashe Peter Zvada, Simbarashe Zvada

Publications

805

Citations

H-Index

Concepts

All Affiliations

University of Cape Town St George's, University of London Uppsala University South African Tuberculosis Vaccine Initiative Stellenbosch University

About

Simbarashe Zvada is an author at University of Cape Town specializing in pharmacotherapy, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	120
2	Pharmacology	3	3	120
3	Health Sciences	1	1	44
4	Nutrition	1	1	43
5	Antibiotics	1	1	44

Simbarashe Zvada

Publications

790

Citations

H-Index

Page 1

	Year	Citations
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis Amina Jindani, Thomas S. Harrison, Andrew Nunn, New England Journal of Medicine	2014	436
CYP2B66, CYP2B618, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe Milcah Dhoro, Simbarashe Zvada, Bernard Ngara, BMC Pharmacology and Toxicology	2015	77
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses Simbarashe Zvada, Paolo Denti, P. R. Donald, Journal of Antimicrobial Chemotherapy	2014	60
Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients Simbarashe Zvada, Paolo Denti, Frederick A. Sirgel, Antimicrobial Agents and Chemotherapy Tuberculosis PreventionPharmacotherapyAntimicrobial ChemotherapyPharmacodynamic ModelingDrug Resistance	2013	44
Effects of Four Different Meal Types on the Population Pharmacokinetics of Single-Dose Rifapentine in Healthy Male Volunteers Simbarashe Zvada, Jan‐Stefan van der Walt, Peter J. Smith, Antimicrobial Agents and Chemotherapy NutritionPharmacokinetic ModelingMedicineTuberculosisRifapentine Exposure	2010	43
Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary Tuberculosis and the Effect of Intermittent High-Dose Rifapentine Simbarashe Zvada, Paolo Denti, Hennie Geldenhuys, Antimicrobial Agents and Chemotherapy Pulmonary TuberculosisMoxifloxacin PharmacokineticsMedicineMoxifloxacin Population PharmacokineticsMoxifloxacin Exposure	2012	33
In Vitro and in Silico Identification and Characterization of Thiabendazole as a Mechanism-Based Inhibitor of CYP1A2 and Simulation of Possible Pharmacokinetic Drug-Drug Interactions Roslyn Thelingwani, Simbarashe Zvada, Hugues Dolgos, Drug Metabolism and Disposition	2009	28
A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine Jose Francis, Simbarashe Zvada, Paolo Denti, Antimicrobial Agents and Chemotherapy	2019	27
Pharmacometrics: Opportunity for Reducing Disease Burden in the Developing World: The Case of Africa Goonaseelan Pillai, Geraint Davies, Paolo Denti, CPT Pharmacometrics & Systems Pharmacology	2013	26
Does Hepatic Impairment Affect the Exposure of Monoclonal Antibodies? Qin Sun, Shirley K. Seo, Simbarashe Zvada, Clinical Pharmacology & Therapeutics	2020	16

Page 1